MedPath

Capreomycin

Generic Name
Capreomycin
Brand Names
Capastat
Drug Type
Small Molecule
Chemical Formula
C50H88N28O15
CAS Number
11003-38-6
Unique Ingredient Identifier
232HYX66HC

Overview

Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus.

Indication

Used in the treatment of tuberculosis in combination with other drugs.

Associated Conditions

  • Tuberculosis (TB)

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
Capreomycin Sulfate for Injection
国药准字H41025458
化学药品
注射剂
9/4/2020
Capreomycin Sulfate for Injection
国药准字H50020691
化学药品
注射剂
9/30/2020
Capreomycin Sulfate for Injection
国药准字H20055189
化学药品
注射剂
4/2/2020
Capreomycin Sulfate for Injection
国药准字H21022195
化学药品
注射剂
9/2/2020
Capreomycin Sulfate for Injection
国药准字H20094030
化学药品
注射剂
4/2/2020
Capreomycin Sulfate for Injection
国药准字H20030042
化学药品
注射剂
3/26/2020
Capreomycin Sulfate for Injection
国药准字H20040448
化学药品
注射剂
3/26/2020
Capreomycin Sulfate for Injection
国药准字H20030041
化学药品
注射剂
3/26/2020
Capreomycin Sulfate for Injection
国药准字H20183426
化学药品
注射剂
8/23/2023
Capreomycin Sulfate for Injection
国药准字H20183427
化学药品
注射剂
8/23/2023

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
Capastat powder for injection vial
28633
Medicine
A
11/4/1991

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.